Genome editing with CRISPR–Cas9 is beginning to be used clinically; promising results to date inspire hope for broad medical impact and mindfulness about safety. A new study shows that when Cas9 cuts its target, a fraction of the time, the target chromosome experiences a breakage process known as chromothripsis, thus prompting efforts to understand the potential negative consequences of this phenomenon and ways to mitigate them.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A cleavage rule for selection of increased-fidelity SpCas9 variants with high efficiency and no detectable off-targets
Nature Communications Open Access 16 September 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carroll, D. Annu. Rev. Biochem. 83, 409–439 (2014).
Frangoul, H. et al. N. Engl. J. Med. 384, 252–260 (2021).
Porteus, M. H. N. Engl. J. Med. 380, 947–959 (2019).
Leibowitz, M. L. et al. Nat. Genet. https://doi.org/10.1038/s41588-021-00838-7 (2021).
Knott, G. J. & Doudna, J. A. Science 361, 866–869 (2018).
Alanis-Lobato, G. et al. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2004832117 (2021).
Brunet, E. et al. Proc. Natl Acad. Sci. USA 106, 10620–10625 (2009).
Stephens, P. J. et al. Cell 144, 27–40 (2011).
Orkin, S. H. & Bauer, D. E. Annu. Rev. Med. 70, 257–271 (2019).
Piel, F. B., Steinberg, M. H. & Rees, D. C. N. Engl. J. Med. 376, 1561–1573 (2017).
Ribeil, J.-A. et al. N. Engl. J. Med. 376, 848–855 (2017).
Esrick, E. B. et al. N. Engl. J. Med. 384, 205–215 (2021).
Chu, S. H. et al. CRISPR J. 4, 169–177 (2021).
Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).
Kohn, D. B., Sadelain, M. & Glorioso, J. C. Nat. Rev. Cancer 3, 477–488 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.U. is a scientific co-founder of Tune Therapeutics.
Rights and permissions
About this article
Cite this article
Urnov, F.D. CRISPR–Cas9 can cause chromothripsis. Nat Genet 53, 768–769 (2021). https://doi.org/10.1038/s41588-021-00881-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-021-00881-4
This article is cited by
-
A cleavage rule for selection of increased-fidelity SpCas9 variants with high efficiency and no detectable off-targets
Nature Communications (2023)
-
Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage
Nature Biotechnology (2022)
